Investigational drug · Phase 3
Masitinib
Also called: AB1010
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
38
Any phase or sponsor naming "Masitinib"
First trial start
2021
Feb 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Masitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Masitinib" as an intervention, largest first.
- Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisPivotal-lookingSuspended
AB ScienceIndustry
NCT05441488 · 800 participants (planned) · Start Jun 28, 2022 · Primary completion Dec 2028
Drug: Placebo; Masitinib (4.5) · For: Progressive Multiple Sclerosis
Sites: Créteil, France; Lille, France; Nice, France · 37 sites in all
- Masitinib in Patients With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
AB ScienceIndustry
NCT01872598 · 721 participants · Start Jan 2012 · Primary completion Dec 2020
Drug: Masitinib; Placebo and 1 more · For: Alzheimer Disease
Sites: Varna, Bulgaria; Thessaloniki, Greece; Bialystok, Poland · 6 sites in all
- Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate CancerPivotal-lookingCompleted
AB ScienceIndustry
NCT03761225 · 714 participants · Start Sep 2014 · Primary completion Dec 15, 2020
Drug: Masitinib; Docetaxel and 2 more · For: Metastatic Castrate Resistant Prostate Cancer
Sites: Sherbrooke, Canada; Nancy, France; Lucknow, India · 9 sites in all
- Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisPivotal-lookingCompleted
AB ScienceIndustry
NCT01433497 · 656 participants · Start Aug 2011 · Primary completion Sep 2019
Drug: Masitinib; Placebo · For: Multiple Sclerosis, Secondary Progressive; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Relapse Free
Sites: Sofia, Bulgaria; Lille, France; Montpellier, France · 8 sites in all
- Masitinib in Patients With Mild Alzheimer's DiseasePivotal-lookingNot yet recruiting
AB ScienceIndustry
NCT05564169 · 600 participants (planned) · Start Jun 2026 · Primary completion Dec 2028
Drug: Placebo; Masitinib (4.5) and 1 more · For: Alzheimer Disease
Sites: Paris, France; Albacete, Spain; Barcelona, Spain · 9 sites in all
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsPivotal-lookingRecruiting
AB ScienceIndustry
NCT03127267 · 495 participants (planned) · Start Feb 2, 2021 · Primary completion Dec 2027
Drug: Masitinib (6.0); Riluzole and 2 more · For: Amyotrophic Lateral Sclerosis
Sites: Birmingham, Alabama; Los Angeles, California; Lexington, Kentucky · 56 sites in all
- Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral CorticosteroidsPivotal-lookingCompleted
AB ScienceIndustry
NCT01449162 · 420 participants · Start Jan 2011 · Primary completion Nov 2019
Drug: Masitinib; Placebo · For: Asthma
Sites: Pleven, Bulgaria; Mělník, Czechia; Brest, France · 8 sites in all
- Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsPivotal-lookingNot yet recruiting
AB ScienceIndustry
NCT07174492 · 412 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2028
Drug: Masitinib 4.5 mg/kg/day; Placebo and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Athens, Greece
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingCompleted
AB ScienceIndustry
NCT02588677 · 394 participants · Start Apr 2013 · Primary completion Dec 5, 2016
Drug: Masitinib (4.5); Riluzole and 2 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Madrid, Spain
- Masitinib Plus Gemcitabine in Pancreatic CancerPivotal-lookingCompleted
AB ScienceIndustry
NCT03766295 · 377 participants · Start Jul 2014 · Primary completion Dec 2020
Drug: Masitinib; Gemcitabine and 1 more · For: Locally Advanced or Metastatic Pancreatic Cancer
Sites: Bruges, Belgium; Limoges, France; Longjumeau, France · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Masitinib-loaded poly(lactic-co-glycolic acid) nanoparticles reinstate lysosomal acidification and drive immunomodulation in Alzheimer's disease.
Huang Q, Chen Y, Liu Y, et al. · J Control Release 2026
- The Role of SOD1 and Oxidative Stress in Amyotrophic Lateral Sclerosis: An Overview.
Gómez-Pérez CA, Ramírez-García MÁ, Yescas-Gómez P · Int J Mol Sci 2026
- Identification of molecular subtypes in clear cell renal cell carcinoma based on chromatin regulators and tumor immune microenvironment profiling.
Chen L, Wu Q, Hong C, et al. · Biochem Biophys Res Commun 2026
- The efficacy of donepezil combination therapy strategies in Alzheimer's disease: A systematic review and network meta-analysis.
Ning X, Xiao Y, Wang N, et al. · J Alzheimers Dis 2026
- Small-Molecule NANT Therapeutics Targeting the Brain-Immune Axis in Alzheimer's Disease: Mechanisms, Clinical Progress, and Translational Challenges.
Sharma N, An SSA · Molecules 2026
- Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer Cells and Organotypic Tumor Slice Culture.
Gupta R, Singh J, Shetty SD, et al. · ACS Omega 2026
Also in development for Amyotrophic Lateral Sclerosis
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.